Evaluation of the 5-HT2C agonist lorcaserin as potential treatment for cocaine ab

5-HT2C 激动剂氯卡色林作为可卡因抗体潜在治疗方法的评估

基本信息

项目摘要

DESCRIPTION (provided by applicant): The positive reinforcing properties of drugs of abuse are thought to result from enhanced activity in meso-limbic dopamine (DA) systems. In addition to direct blockade of DA transmission by classical and atypical antipsychotics, an alternative approach to diminishing central DA activity is via stimulation of serotonin 5-HT2C receptors. The research described in the present proposal will evaluate one such 5-HT2C agonist lorcaserin, already well advanced in clinical development in other indications, for its attenuation of cocaine abuse-related behavior in the rhesus monkey. Data obtained in this non-human primate (NHP) should better predict clinical effects in humans than data from rodents. The aim is to determine whether the NHP data would provide encouragement, or not, for the clinical testing of lorcaserin for treating cocaine abuse in humans. The experiments will evaluate lorcaserin for attenuation of cocaine-induced hyperactivity; cocaine maintained self-administration behavior and the internal stimulus properties of cocaine in a drug discrimination procedure. To demonstrate that lorcaserin could be useful for treating cocaine abuse in humans, these experiments should show that lorcaserin is effective in attenuating cocaine abuse- related behavior in NHP at doses without intrinsic effects on behavior.
描述(由申请人提供):滥用药物的正强化特性被认为是由于中脑边缘多巴胺(DA)系统的活性增强。除了通过经典和非典型抗精神病药直接阻断DA传递外,减少中枢DA活性的另一种方法是通过刺激5-羟色胺5-HT 2C受体。本提案中描述的研究将评估一种这样的5-HT 2C激动剂氯卡色林,其在其他适应症的临床开发中已经很先进,用于减轻恒河猴中可卡因滥用相关行为。在这种非人灵长类动物(NHP)中获得的数据应该比啮齿类动物的数据更好地预测人类的临床效果。其目的是确定NHP数据是否会为氯卡色林治疗人类可卡因滥用的临床试验提供鼓励。该实验将评价氯卡色林对可卡因诱导的多动症的减弱作用;可卡因在药物辨别程序中维持自我给药行为和可卡因的内部刺激特性。为了证明氯卡色林可用于治疗人类的可卡因滥用,这些实验应显示氯卡色林在对行为没有内在影响的剂量下有效减弱NHP中的可卡因滥用相关行为。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHARLES P FRANCE其他文献

CHARLES P FRANCE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHARLES P FRANCE', 18)}}的其他基金

Methocinnamox (MCAM): A novel opioid receptor antagonist
Methocinnamox (MCAM):一种新型阿片受体拮抗剂
  • 批准号:
    10844948
  • 财政年份:
    2023
  • 资助金额:
    $ 40.56万
  • 项目类别:
A novel opioid receptor antagonist for treating abuse and overdose
一种用于治疗滥用和过量的新型阿片受体拮抗剂
  • 批准号:
    9892987
  • 财政年份:
    2019
  • 资助金额:
    $ 40.56万
  • 项目类别:
A novel opioid receptor antagonist for treating abuse and overdose
一种用于治疗滥用和过量的新型阿片受体拮抗剂
  • 批准号:
    10353379
  • 财政年份:
    2019
  • 资助金额:
    $ 40.56万
  • 项目类别:
Methocinnamox (MCAM): A novel õ-opioid receptor antagonist for opioid use disorders
Methocinnamox (MCAM):一种新型 α-阿片受体拮抗剂,用于治疗阿片类药物使用障碍
  • 批准号:
    10477526
  • 财政年份:
    2019
  • 资助金额:
    $ 40.56万
  • 项目类别:
Methocinnamox (MCAM): A novel õ-opioid receptor antagonist for opioid use disorders
Methocinnamox (MCAM):一种新型 α-阿片受体拮抗剂,用于治疗阿片类药物使用障碍
  • 批准号:
    10763458
  • 财政年份:
    2019
  • 资助金额:
    $ 40.56万
  • 项目类别:
A novel opioid receptor antagonist for treating abuse and overdose
一种用于治疗滥用和过量的新型阿片受体拮抗剂
  • 批准号:
    10092999
  • 财政年份:
    2019
  • 资助金额:
    $ 40.56万
  • 项目类别:
A novel opioid receptor antagonist for treating abuse and overdose
一种用于治疗滥用和过量的新型阿片受体拮抗剂
  • 批准号:
    10561706
  • 财政年份:
    2019
  • 资助金额:
    $ 40.56万
  • 项目类别:
Evaluation of the 5-HT2C agonist lorcaserin as potential treatment for cocaine ab
5-HT2C 激动剂氯卡色林作为可卡因抗体潜在治疗方法的评估
  • 批准号:
    9008117
  • 财政年份:
    2013
  • 资助金额:
    $ 40.56万
  • 项目类别:
Evaluation of the 5-HT2C agonist lorcaserin as potential treatment for cocaine ab
5-HT2C 激动剂氯卡色林作为可卡因抗体潜在治疗方法的评估
  • 批准号:
    8652970
  • 财政年份:
    2013
  • 资助金额:
    $ 40.56万
  • 项目类别:
Training in Drug Abuse Research: Behavior and Neurobiology
药物滥用研究培训:行为和神经生物学
  • 批准号:
    8266367
  • 财政年份:
    2011
  • 资助金额:
    $ 40.56万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 40.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 40.56万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 40.56万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 40.56万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 40.56万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 40.56万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 40.56万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 40.56万
  • 项目类别:
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 40.56万
  • 项目类别:
    Idea to Innovation
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 40.56万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了